Delayed therapy of experimental ischemia with competitive n-methyl-d-aspartate antagonists in rabbits

Stroke

Volumn 24, Issue 7, 1993, Pages 1068-1071

  Madden, Kenneth P ^a   Clark, Wayne M ^b   Zivin, Justin A ^c  

^a MARSHFIELD CLINIC   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

N methyl D aspartate; Neuronal damage; Rabbits; Spinal cord

Indexed keywords

4 (2H TETRAZOL 5 YLMETHYL) 2 PIPERIDINECARBOXYLIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DOSE RESPONSE; NONHUMAN; PARAPLEGIA; PRIORITY JOURNAL; RABBIT;

ANIMAL; ISCHEMIA; N-METHYLASPARTATE; PARAPLEGIA; PIPECOLIC ACIDS; RABBITS; RECEPTORS, N-METHYL-D-ASPARTATE; SPINAL CORD; SUPPORT, NON-U.S. GOV'T; TETRAZOLES; TIME FACTORS;

EID: 0027300760     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/01.STR.24.7.1068     Document Type: Article

References (15)

1. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol. 1986;19:105-111.
2. Albers GW, Goldberg MP, Choi DW. N-methyl-D-aspartate antagonists: ready for clinical trials in brain ischemia? Ann Neurol. 1989;25:398-403.
3. Schoepp DD, Ornstein PL, Leander JD, Lodge D, Salhoff CR, Zimmerman DM. Pharmacologic characterization of LY233053: a structurally novel tetrazole-substituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action. J Pharmacol Exp Ther. 1990;255:1301-1308.
4. Clark WM, Madden KP, Zivin JA. Efficacy of CGS19755, a competitive glutamate antagonist, following experimental CNS ischemia. Ann Neurol. 1991;30:235. Abstract.
5. Madden KP, Clark WM, Kochhar A, Zivin JA. Therapeutic efficacy of LY-233053, a competitive glutamate antagonist, in experimental CNS ischemia. J Neurosurg. 1992;76:106-110.
6. Zivin JA, DeGirolami U, Hurwitz EL. Spectrum of neurological deficits in experimental CNS ischemia. Arch Neurol. 1982;39:408-412.
7. Winer BJ. Statistical Principles in Experimental Design. New York, NY: McGraw-Hill Book Co; 1971.
8. Zivin JA, Waud DR. Quantal bioassay and stroke. Stroke. 1992;23:767-773.
9. Jones TH, Morewetz RB, Crowell RM, Marcoux FW, FitzGibbon SJ, DeGirolami U, Ojemann RG. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg. 1981;54:773-782.
10. Traupe H, Kruse E, Heiss WD. Reperfusion of focal ischemia of varying duration: postischemic hyper- and hypo-perfusion. Stroke. 1982;13:615-622.
11. Dujovny M, Osgood CP, Barrioneuvo PJ, Hellstrom R, Laha RK. Middle cerebral artery microneurosurgical embolectomy. Surgery. 1976;80:336-339.
12. Roman R, Bartkowski H, Simon R. The specific NMDA receptor antagonist AP-7 attenuates focal ischemic brain injury. Neurosci Lett. 1989;104:19-24.
13. Grotta JC, Picone CM, Ostrow PT, Strong RA, Earls RM, Yao LP, Rhoades HM, Dedman JR. CGS-19755, a competitive NMDA antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. Ann Neurol. 1990;27:612-619.
14. Chen M, Bullock R, Graham DI, Frey P, Lowe D, McCulloch J. Evaluation of a competitive NMDA antagonist (D-CPPene) in feline focal cerebral ischemia. Ann NeuroL 1991;30:62-70.
15. Barsan WG, Brott TG, Olinger CP, Adams HJ, Haley EJ, Levy DE. Identification and entry of the patient with acute cerebral infarction. Ann Emerg Med. 1988;17:1192-1195.